{
    "clinical_study": {
        "@rank": "3200", 
        "arm_group": [
            {
                "arm_group_label": "Balugrastim 300 ug/kg", 
                "arm_group_type": "Experimental", 
                "description": "Balugrastim 300 \u03bcg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles"
            }, 
            {
                "arm_group_label": "Balugrastim 670 \u03bcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Balugrastim 670 \u03bcg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles"
            }, 
            {
                "arm_group_label": "Filgrastim 5 \u03bcg/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Filgrastim will be administered at a dose of 5 \u03bcg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to \u22652*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to find the optimal dose of balugrastim by\n      characterizing its pharmacokinetics (PK), and by comparing the pharmacodynamics (PD) of\n      balugrastim to filgrastim in children receiving chemotherapy."
        }, 
        "brief_title": "Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histological or cytologically-confirmed solid tumor in a patient for whom the study\n             chemotherapy regimen [Vincristine plus ifosfamide plus doxorubicin plus etoposide\n             (VIDE), Vincristine plus doxorubicin plus cyclophosphamide alternating with\n             ifosfamide plus etoposide (VDC/IE), Ifosfamide plus vincristine plus actinomycin D\n             (IVA) or Ifosfamide plus vincristine plus Adriamycin (IVAd)] is considered an\n             appropriate treatment.\n\n          2. Minimum body weight of 15 kg\n\n          3. Life expectancy of at least 3 months with appropriate therapy\n\n          4. Female or male children and adolescents aged 2 to 17 years\n\n          5. Written informed consent provided by parent(s)/legal representative(s) of the\n             pediatric patient and patient's assent if appropriate at the time of screening.\n\n          6. Fertile patients (male or female) must use highly reliable contraceptive measures.\n\n          7. Female patients who have attained menarche must have a negative urine pregnancy test\n             at the screening visit.\n\n          8. White blood cell (WBC) count >2.5*10^9/L, ANC \u22651.5*10^9/L, and platelet count\n             \u2265100*10^9/L (at screening and prior to chemotherapy)\n\n        Exclusion Criteria:\n\n          1. Primary myeloid disorders\n\n          2. Prior radiation therapy within 4 weeks of randomization into this study.\n\n          3. Previous exposure to filgrastim, pegfilgrastim, lenograstim or other G-CSF less than\n             6 months before randomization.\n\n          4. Known hypersensitivity to filgrastim, pegfilgrastim, lenograstim or any balugrastim\n             excipients\n\n          5. Pregnancy or breastfeeding (if a patient becomes pregnant during the study she will\n             be withdrawn from the study).\n\n          6. Major surgery, serious infection, within 3 weeks before first administration of study\n             drug, serious trauma or compound medical procedure within the 4 weeks prior to the\n             first study drug dose.\n\n          7. Subjects with a clinically significant or unstable medical or surgical condition that\n             would preclude safe and complete study participation, as determined by medical\n             history, physical exams, ECG, laboratory tests or imaging."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940601", 
            "org_study_id": "NEUGR-005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Balugrastim 300 ug/kg", 
                    "Balugrastim 670 \u03bcg/kg"
                ], 
                "description": "Balugrastim 300 ug/kg and Balugrastim 670 ug/kg", 
                "intervention_name": "Balugrastim", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Filgrastim 5 \u03bcg/kg", 
                "description": "Filgrastim 5 \u03bcg/kg", 
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "solid tumors", 
            "balugrastim"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Teva Investigational Site 59070"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Teva Investigational Site 59068"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Teva Investigational Site 59069"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Teva Investigational Site 54054"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tbilisi", 
                        "country": "Georgia"
                    }, 
                    "name": "Teva Investigational Site 81021"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Teva Investigational Site 51063"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary"
                    }, 
                    "name": "Teva Investigational Site 51064"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }, 
                    "name": "Teva Investigational Site 52052"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }, 
                    "name": "Teva Investigational Site 52053"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cluj-Napoca", 
                        "country": "Romania"
                    }, 
                    "name": "Teva Investigational Site 52054"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iasi", 
                        "country": "Romania"
                    }, 
                    "name": "Teva Investigational Site 52055"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50161"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ekaterinburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50166"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krasnodar", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50163"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50164"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50165"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50167"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Teva Investigational Site 50162"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bansk\u00e1 Bystrica", 
                        "country": "Slovakia"
                    }, 
                    "name": "Teva Investigational Site 62018"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }, 
                    "name": "Teva Investigational Site 62019"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ko\u0161ice", 
                        "country": "Slovakia"
                    }, 
                    "name": "Teva Investigational Site 62020"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dnipropetrovsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Teva Investigational Site 58100"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Teva Investigational Site 58104"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Teva Investigational Site 58101"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Teva Investigational Site 58103"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lviv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Teva Investigational Site 58102"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Czech Republic", 
                "Georgia", 
                "Hungary", 
                "Romania", 
                "Russian Federation", 
                "Slovakia", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open Label, Randomized, Active Controlled, Dose Finding Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim at Doses of 300 \u00b5g/kg and 670 \u00b5g/kg in Pediatric Patients Diagnosed With Solid Tumors Receiving Chemotherapy", 
        "overall_contact": {
            "last_name": "Teva US Medical Information", 
            "phone": "1-800-896-5855"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Bulgaria: Ministry of Health", 
                "Hungary: National Institute of Pharmacy", 
                "Romania: National Medicines Agency", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Ukraine: Ministry of Health", 
                "Poland: Ministry of Health", 
                "Georgia: Ministry of Health", 
                "Czech Republic: State Institute for Drug Control", 
                "Slovakia: State Institute for Drug Control"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the curve (AUC) of absolute neutrophil count (ANC)", 
            "safety_issue": "No", 
            "time_frame": "Day 1 to 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940601"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ANC nadir (measured in 10^9/L), which is the lowest ANC recorded", 
                "measure": "ANC nadir", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "description": "Time to ANC nadir, which is the time from the beginning of chemotherapy up to the occurrence of the ANC nadir", 
                "measure": "Time to ANC nadir", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "description": "Time to ANC recovery (ANC >1.5*10^9/L) from nadir within each treatment cycle", 
                "measure": "Time to ANC recovery", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "description": "Number of days subject experiences severe neutropenia (ANC <0.5*10^9/L)", 
                "measure": "Duration of severe neutropenia (DSN)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "description": "Proportion of subjects who experience  severe neutropenia (ANC <0.5*10^9/L)", 
                "measure": "Incidence of severe neutropenia", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "description": "Frequency of febrile neutropenia (defined as body temperature >38.5\u00b0C for more than one hour [axillary measurement] and ANC <0.5*10^9/L) by cycle and across all cycles.", 
                "measure": "Frequency of febrile neutropenia", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "measure": "Summary of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of informed consent to 16 weeks"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}